Premium
Anticonvulsant action of a NMDA receptor antagonist CGP 40116 varies only quantitatively during ontogeny in rats
Author(s) -
Haugvicová R,
Mareš P
Publication year - 1998
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.1998.tb00981.x
Subject(s) - anticonvulsant , pentylenetetrazol , antagonist , nmda receptor , ontogeny , 2 amino 5 phosphonovalerate , tonic (physiology) , excitatory postsynaptic potential , pharmacology , epilepsy , chemistry , receptor , medicine , endocrinology , excitatory amino acid antagonists , biology , neuroscience , biochemistry
Summary— Anticonvulsant action of CGP 40116, a competitive antagonist of N‐methyl‐D‐aspartate type of excitatory amino acid receptors, was studied in rats during development (7, 12, 18, 25 and 90 days old). Two types of motor seizures were elicited by a subcutaneous injection of pentylenetetrazol. Pretreatment with CGP 40116 did not influence minimal, predominantly clonic seizures in any age group. Generalized tonic‐clonic seizures were at first modified — their tonic phase was restricted to forelimbs, then selectively suppressed — and with increasing dosage the clonic phase was blocked too. This effect exhibited only minor quantitative changes during development.